Priothera

Priothera is leading the way in developing mocravimod, a S1P receptor modulator as an adjunctive immune therapy to allo-HSCT.

S1P receptor modulators largely reduce the egress of T-cell subsets from lymphatic tissues and are thereby suggested to inhibit graft-versus-host disease (GvHD) while at the same time enhancing graft-versus-leukemia benefits in patients receiving allogeneic Hematopoietic Stem Cell Transplantation (HSCT).

Priothera is developing mocravimod (KRP203) to significantly improve the clinical outcome of allo-HSCT. Mocravimod has been studied in pre-clinical stem cell transplantation models and has shown a survival benefit. In addition, mocravimod was safe and well tolerated and showed efficacy in patients with hematological malignancies undergoing allo-HSCT.